Upgrade to SI Premium - Free Trial

Protagonist Therapeutics (PTGX)

97.38 -5.41 (5.26%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Form 4 Protagonist Therapeutics For: May 29 Filed by: Waddill William D. June 1, 2026 6:31 PM - SEC Filing Form 144 Protagonist Therapeutics Filed by: Waddill William D. May 29, 2026 4:23 PM - SEC Filing Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026 May 28, 2026 7:05 AM - StreetInsider Wolfe Research Starts Protagonist Therapeutics (PTGX) at Outperform May 21, 2026 5:32 AM - StreetInsider Form 4/A Protagonist Therapeutics For: May 12 Filed by: PATEL DINESH V PH D May 14, 2026 8:07 PM - SEC Filing Form 4 Protagonist Therapeutics For: May 12 Filed by: PATEL DINESH V PH D May 12, 2026 7:28 PM - SEC Filing Form 144 Protagonist Therapeutics Filed by: PATEL DINESH V PH D May 12, 2026 5:30 PM - SEC Filing Form SCHEDULE 13G Protagonist Therapeutics Filed by: STATE STREET CORP May 12, 2026 11:51 AM - SEC Filing Form 4 Protagonist Therapeutics For: May 07 Filed by: Giraudo Bryan May 11, 2026 8:26 PM - SEC Filing BMO Capital Reiterates Outperform Rating on Protagonist Therapeutics (PTGX) May 11, 2026 9:22 AM - StreetInsider Form 144 Protagonist Therapeutics Filed by: Giraudo Bryan May 8, 2026 4:23 PM - SEC Filing Form 144 Protagonist Therapeutics Filed by: Giraudo Bryan May 7, 2026 5:22 PM - SEC Filing Form 144 Protagonist Therapeutics Filed by: Giraudo Bryan May 7, 2026 4:49 PM - SEC Filing Protagonist Therapeutics (PTGX) PT Raised to $137 at Citizens May 6, 2026 4:28 AM - StreetInsider Protagonist Therapeutics (PTGX) Tops Q1 EPS by 54c May 5, 2026 5:24 PM - StreetInsider Form 10-Q Protagonist Therapeutics For: Mar 31 May 5, 2026 4:27 PM - SEC Filing Form 8-K Protagonist Therapeutics For: May 05 May 5, 2026 4:09 PM - SEC Filing Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update May 5, 2026 4:05 PM - StreetInsider Form SCHEDULE 13G Protagonist Therapeutics Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 30, 2026 11:57 AM - SEC Filing Form SCHEDULE 13G Protagonist Therapeutics Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC April 29, 2026 2:43 PM - SEC Filing Form ARS Protagonist Therapeutics For: Dec 31 April 28, 2026 4:55 PM - SEC Filing Form DEFA14A Protagonist Therapeutics April 28, 2026 4:51 PM - SEC Filing Form DEF 14A Protagonist Therapeutics For: Jun 17 April 28, 2026 4:45 PM - SEC Filing Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration April 28, 2026 9:05 AM - StreetInsider Form 4 Protagonist Therapeutics For: Apr 23 Filed by: PATEL DINESH V PH D April 24, 2026 4:11 PM - SEC Filing Form 4 Protagonist Therapeutics For: Apr 20 Filed by: Ali Asif April 21, 2026 4:59 PM - SEC Filing Form 144 Protagonist Therapeutics Filed by: Ali Asif April 21, 2026 4:58 PM - SEC Filing Protagonist Therapeutics Reports Granting of Inducement Awards April 16, 2026 4:05 PM - StreetInsider Jefferies stays Buy on Protagonist Therapeutics (PTGX) amid JNJ's bullish tone on Icotyde April 14, 2026 3:13 PM - StreetInsider Protagonist Therapeutics (PTGX) PT Raised to $121 at Truist Securities April 14, 2026 1:01 PM - StreetInsider Protagonist Therapeutics (PTGX) PT Raised to $116 at Clear Street April 6, 2026 4:06 PM - StreetInsider Protagonist presents one-year ICOTYDE psoriasis data at AAD meeting March 28, 2026 10:05 AM - StreetInsider Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting March 28, 2026 10:05 AM - StreetInsider Form 4 Protagonist Therapeutics For: Mar 26 Filed by: MOLINA ARTURO MD March 27, 2026 7:36 PM - SEC Filing Form 4 Protagonist Therapeutics For: Mar 26 Filed by: SELICK HAROLD E March 27, 2026 7:35 PM - SEC Filing Form 4 Protagonist Therapeutics For: Mar 26 Filed by: Ali Asif March 27, 2026 7:34 PM - SEC Filing Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: VANGUARD GROUP INC March 27, 2026 11:33 AM - SEC Filing Form 144 Protagonist Therapeutics Filed by: SELICK HAROLD E March 26, 2026 4:06 PM - SEC Filing Form 144 Protagonist Therapeutics Filed by: Ali Asif March 26, 2026 4:05 PM - SEC Filing Form 144 Protagonist Therapeutics Filed by: MOLINA ARTURO MD March 26, 2026 4:02 PM - SEC Filing Form 4 Protagonist Therapeutics For: Mar 23 Filed by: PATEL DINESH V PH D March 25, 2026 7:23 PM - SEC Filing Form 144 Protagonist Therapeutics Filed by: PATEL DINESH V PH D March 24, 2026 5:57 PM - SEC Filing Protagonist Therapeutics (PTGX) PT Raised to $104 at Clear Street March 18, 2026 3:39 PM - StreetInsider Protagonist Therapeutics (PTGX) PT Raised to $119 at Barclays following Icotyde approval March 18, 2026 12:17 PM - StreetInsider Protagonist Therapeutics (PTGX) PT Raised to $121 at Jefferies March 18, 2026 12:14 PM - StreetInsider Truist Securities models $730M peak revenue for Protagonist Therapeutics (PTGX) in Icotyde royalties March 18, 2026 10:28 AM - StreetInsider Protagonist receives FDA approval for psoriasis drug ICOTYDE March 18, 2026 8:05 AM - StreetInsider Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis March 18, 2026 8:05 AM - StreetInsider Full Article List